跳至主要内容
临床试验/DRKS00029126
DRKS00029126招募中不适用

Systematic retrospective evaluation of patients with sarcoidosis treated with the Havelhöher Sarcoidosis Therapy Protocol (HSP)

Wala Heilmittel GmbH Pharmakologische und klinische Forschung0 个研究点目标入组 150 人开始时间: 2022年7月8日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
150

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 Years 至 85 Years(—)
性别
All

入选标准

  • 1) Clinically and/or histologically confirmed diagnosis of sarcoidosis in the years 2005 to 2020.
  • 2) Treatment with HSP
  • 3) Documentation of therapy in the Turbomed database of the outpatient clinic or in Clinixx- documentation of the pulmonary department of the gemeinschaftskrankenhaus Havelhoehe
  • 4) Age at least 18 years
  • 5) Legal capacity
  • 6) Voluntary and written informed consent before the start of the study.

排除标准

  • 1) Clinically relevant concomitant conditions that unduly limit the assessment of efficacy and tolerability. These include:
  • - confirmed autoimmune diseases
  • - active tumor diseases
  • - acute sarcoidosis (Löfgren's syndrome)
  • - treatment with less than 1 cycle of HSP
  • - incomplete data set (i.e., less than 2 radiographs during the course, less than 2 clinically defined measurement parameters documented below 80%)

研究者

发起方
Wala Heilmittel GmbH Pharmakologische und klinische Forschung

相似试验

Systematic retrospective evaluation of patients with... | 临床试验